Will West

Will West is a biotechnology chief executive and investment advisor with experience spanning basic research through to late-stage clinical trials. They are CEO of CellCentric (2004–present), which is developing inobrodib (CCS1477), and they serve as an investment advisor to Morningside (2019–present) and as a non-executive director of Cyted Health (2020–present), F2G (2020–present) and Mevox Ltd. (2025–present). They previously held roles including post‑doctoral research scientist at NIBSC (1992–1994), Clinical Group Head at Procter & Gamble (1994–2001), Director of Development at CellFactors (2001–2004), Non‑Executive Director at PlaqueTec (2012–2016), Director at Cancer Targeting Systems (2014–2020), Council Member of the BBSRC (2011–2015), Non‑Executive Director of the BioIndustry Association (2013–2020), and Chair of the John Innes Centre (2018–2021) and VaxEquity (2020–2025). They earned a PhD in Virology/Immunology from the University of Newcastle-upon-Tyne (1989–1992), an MSc in Clinical Research from Cardiff University (1997–1999), and an MBA (Executive) from London Business School (1999–2001).